Clin2
NCT03889899Possibly a fitRecruiting

Device treatment for certain skin, mouth, or surface soft tissue cancers

Skin CancerMucosal Neoplasm of Oral CavitySoft Tissue Neoplasm

Part of Cancer, Infections, Mouth & dental, Skin clinical trials.

This trial studies a radiation-emitting device (DaRT) to treat certain cancers on the skin, in the mouth, or in superficial soft tissues. You may qualify if you have a confirmed malignant tumor, enough body strength for treatment, and blood tests and pregnancy status that meet safety limits.

Summary written for real people, not researchers, by Clin2.

Phase
N/A
Enrollment
30 people
Ages
18 years and older
Study type
Interventional

Who can take part

  • You are age 18 or older.
  • You have a confirmed cancer in the skin, mouth lining, or superficial soft tissue (including superficial soft tissue sarcoma).
  • Your tumor is measurable and no larger than 7 cm at its widest point.
  • Your health status is good enough (ECOG less than 2) and you’re expected to live more than 6 months.
  • Your blood test and safety labs meet limits (platelets at least 100,000; clotting test INR 1.8 or lower; kidney test creatinine 1.9 or lower).
  • If you could become pregnant, you must have a negative pregnancy test; you must not be pregnant or breastfeeding; you must be willing to sign consent.

View the official record on ClinicalTrials.gov

Quick eligibility check

Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.

Similar studies

Other trials that look related to this one.

NCT04534127Recruiting
DaRT radiation device for skin and mouth or superficial tumors

This trial tests a targeted radiation device (DaRT seeds) to treat certain cancers on the skin, in the mouth, or in superficial soft tissue. It may help when standard treatment (like surgery or regular radiation/chemo) hasn’t worked, isn’t safe, or isn’t wanted.

Jerusalem
NCT05047094Recruiting
DaRT radiation plus pembrolizumab for head and neck cancer

This trial tests whether a targeted internal radiation treatment (DaRT) combined with pembrolizumab (an immune therapy) can shrink recurrent or metastatic head and neck squamous cell cancer that cannot be fully removed with surgery. It may help by making cancer more visible to the immune system while delivering localized radiation to a tumor area.

Jerusalem
NCT04068155Recruiting
Radiation device for certain skin cancers you can treat locally

This trial tests a radiation-emitting device placed near the tumor to treat certain malignant skin cancers that can be fully covered. It may help shrink or control the cancer at the skin site where the device is applied.

Grenoble
NCT06615635Recruiting
Radiation device trial for skin cancer in patients with weak immune systems

This trial tests a special radiation device (DaRT) placed directly into skin cancer tumors. It is designed for patients with weakened immune systems (immunocompromised) who have a single skin cancer lesion on the skin (not spread elsewhere).

Gilbert, Arizona
NCT07062003Recruiting
Minibeam radiation for skin or soft tissue tumors

This trial tests a new type of radiation called minibeam therapy for people with skin or soft tissue cancers that have come back or spread. It's designed to help shrink tumors that standard treatments haven't worked well for, and it uses a special device to focus the radiation more precisely.

Rochester, Minnesota
NCT05781555Recruiting
DaRT radiation device study for treating tumors

This study tests a radiation-emitting device (called DaRT) for treating cancer tumors. It may help shrink or control malignant tumors and researchers will check safety and response to the treatment.

Jerusalem

Hear when a new Skin Cancer trial opens

We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.